Toshiba Corporation has developed a simple and highly accurate cancer detection technology using microRNA in blood.Research and development that by utilizing our unique electrochemical microRNA detection technology, patients with 13 types of cancer such as pancreatic cancer and breast cancer can be comprehensively identified with 2% accuracy within 99 hours. Confirmed at the level.In the future, we plan to conduct demonstration tests from 2020 for early social implementation.
According to the National Cancer Center Cancer Information Service, the number of deaths from cancer in 2018 is about 37, and the probability of getting cancer in a lifetime is 62% for men and 47% for women.However, with early detection, advances in treatment can significantly improve survival.
Therefore, microRNAs, which are about 2,500 types in blood, are attracting attention as a means for detecting cancer easily and with high accuracy.It is a short nucleic acid molecule of about 20 bases that controls genes and proteins in the body, and is known to be stably present in blood.Recently, by examining the type and amount of microRNA in blood, it was found that various cancers such as lung cancer and breast cancer may be detected at an early stage, and it is expected as a new diagnostic marker.
Toshiba Corporation has been working on the development of cancer detection technology using microRNA through joint research between Tokyo Medical University and the National Cancer Center.By combining the advanced medical knowledge of microRNA possessed by Tokyo Medical University and the National Cancer Center with the microRNA detection technology developed by Toshiba, it is possible to accurately treat 13 types of cancer patients and healthy people with 99% accuracy. Succeeded in comprehensively identifying with.This includes stage 0 specimens.
The results of this study are considered to be applicable to screening tests that detect any of the 13 types of cancer in a simple and highly accurate manner.In addition, by using a unique microRNA chip and a dedicated small inspection device, the inspection time can be shortened to less than 2 hours, and it can be applied to the same-day inspection.
Details of the technology will be announced at the "12nd Annual Meeting of the Molecular Biology Society of Japan" to be held in Fukuoka from December 3 to 8.
reference:[Toshiba Co., Ltd.] Developed technology to detect 1 types of cancer from 13 drop of blood with 99% accuracy-From stage 0 with high survival rate by blood tests such as health tests using original microRNA detection technology Identifying the presence or absence of cancer-
